UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
July 17, 2003
Vicuron Pharmaceuticals Inc.
(Exact Name of Registrant As Specified in its Charter)
Delaware |
|
000-31145 |
|
04-3278032 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission |
|
(I.R.S. Employer |
|
|
|
|
|
455 South Gulph Road, King of Prussia, PA 19406 |
||||
(Address of Principal Executive Offices) (Zip Code) |
||||
|
||||
(610) 205-2300 |
||||
(Registrants telephone number, including area code) |
||||
|
||||
|
||||
(Former Name or Former Address, if Changed Since Last Report.) |
Item 7. Exhibits.
The exhibits listed on the Exhibit Index (following the Signatures section of this report) are included in this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VICURON PHARMACEUTICALS INC. |
||
|
|
(Registrant) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: |
July 17, 2003 |
By: |
|
/s/ George F. Horner III |
|
|
|
George F. Horner III |
|
|
|
|
President and Chief Executive Officer |
|
2
EXHIBIT INDEX
Pursuant to Item 601(a)(2) of Regulation S-K, this exhibit index immediately precedes the exhibits.
Exhibit No. |
|
Description |
1.1
|
|
Form of Underwriting Agreement dated July 17, 2003, by and among the registrant and the underwriters named therein. |
3